Cancer immunotherapy — leveraging the immune system to recognize and destroy cancer cells — has transformed oncology over the past decade, with checkpoint inhibitors achieving durable remissions in cancers previously uniformly fatal (advanced melanoma, NSCLC) and CAR-T cell therapy producing complete responses in heavily pretreated hematological malignancies. Understanding how these therapies work, which patients and tumor types respond, and how to manage their unique toxicity profiles is essential for oncology providers.
Checkpoint Inhibitors: Mechanism and Key Evidence
The CTLA-4, PD-1, and PD-L1 pathways are immune "checkpoints" — mechanisms that prevent autoimmunity by dampening T-cell responses. Tumor cells upregulate PD-L1 to escape immune killing (PD-L1 binds PD-1 on T-cells → T-cell exhaustion/apoptosis). Checkpoint inhibitors (anti-PD-1: nivolumab, pembrolizumab; anti-PD-L1: atezolizumab, durvalumab; anti-CTLA-4: ipilimumab) block these inhibitory interactions → reinvigorate exhausted tumor-infiltrating T-cells. Key efficacy evidence: Melanoma — pembrolizumab vs. ipilimumab (KEYNOTE-006): 5-year OS 39% vs. 17% — the first demonstration of durable long-term survival in advanced melanoma. NSCLC — pembrolizumab monotherapy vs. chemotherapy first-line in PD-L1 ≥50%: 5-year OS 31.9% vs. 16.3% (KEYNOTE-024). The "tail of the curve" — durable responses persisting years after treatment discontinuation — distinguishes immunotherapy from chemotherapy. Tumor mutational burden (TMB) and microsatellite instability-high (MSI-H): tumor-agnostic biomarkers predicting immunotherapy response regardless of tumor type — the basis for pembrolizumab's tumor-agnostic FDA approval (first in oncology history).
Immune-Related Adverse Events (irAEs)
Checkpoint inhibitors can trigger autoimmune-like tissue damage in any organ system — the flip side of unleashing T-cell activity. Most common irAEs: dermatitis (30–40%), colitis (10–20%), hepatitis (5–10%), pneumonitis (5%), endocrinopathy (thyroiditis 20–30%, adrenal insufficiency 5%, hypophysitis 5%). Management principles: Grade 1 (mild): continue immunotherapy + symptomatic treatment; Grade 2 (moderate): hold immunotherapy + prednisone 0.5–1mg/kg/day; Grade 3–4 (severe/life-threatening): discontinue immunotherapy + high-dose IV methylprednisolone + specialist consultation. Endocrine irAEs (thyroid, adrenal, pituitary) often require permanent hormone replacement — immunotherapy may be continued after endocrine irAE stabilization in many cases. For oncology centers managing immunotherapy patients, our laboratory supplies section supports thyroid, cortisol, and inflammatory marker monitoring, and our PPE catalog ensures appropriate protection during high-risk oncology procedures.
